Interferon in the treatment of cutaneous T-cell lymphoma.

Published

Journal Article (Review)

Interferons are polypeptides with a broad range of in vivo effects that have shown efficacy in cutaneous T-cell lymphoma (CTCL). Particularly useful is alfa interferon (IFN) which, as a single agent, has shown partial remission rates of > 50% and complete responses of > 20%. Side-effects are predictable, generally well tolerated and dose-related. The efficacy of IFN has increased with combination therapy without any significant increase in attendant side-effects. An update on the specifics of the different IFN subtypes, their inherent biologic activity, pharmacokinetics, efficacy and safety in CTCL is presented in this paper.

Full Text

Duke Authors

Cited Authors

  • Olsen, EA

Published Date

  • 2003

Published In

Volume / Issue

  • 16 / 4

Start / End Page

  • 311 - 321

PubMed ID

  • 14686974

Pubmed Central ID

  • 14686974

International Standard Serial Number (ISSN)

  • 1396-0296

Language

  • eng

Conference Location

  • United States